text:
Journal of Clinical Lipidology
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians.
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
The Journal of Clinical Lipidology is NOW INCLUDED IN MEDLINE/PUBMED!
Electronic usage:
An increasing number of readers access the journal online via ScienceDirect, one of the world's most advanced web delivery systems for scientific, technical and medical information.
Average monthly article downloads for this journal: 6,615*
* Figure is a monthly average of full-text articles downloaded from ScienceDirect in 2014
• Manuscript Categories
• Studies in humans and animals
• Contributors
• Authorship
• Submission
• Previous presentation or release of informaton
• Article structure
• Essential title page information
• Abstract
• Keywords
• Supplementary material
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism.
Journal of Clinical Lipidology provides rapid online electronic and print publication of the most important current scientific developments in the field of lipids and lipidology. The Journal publishes both clinical and basic original, peer-reviewed articles devoted to diagnosis and treatment lipid disorders. Sections of the Journal address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
Manuscript Categories
Case Studies. Case studies are limited to 4 authors, 8 double-spaced pages total, including text, references (<20), figure legends, and 4 figures. No abstract included.
Reviews. Contemporary and Historical Reviews (Solicited and Unsolicited)
Review articles should contain a brief abstract and be 5000 total words, including references, tables, and figures. References are 30 and must be 5 years old. Use other articles to incorporate older references.
Letters to the Editor. Letters should be double-spaced, not exceeding 450words. Letters will be reviewed and are subject to editing. They should not contain original data or figures. If accepted for publication, a copy of the letter will be sent to the author(s) of the original article, if applicable. The author(s) will have an opportunity to respond with new material that will be considered for publication with the letter.
Editorial Commentary. All articles by invitation only
Commentaries should be confined to articles in the current issue or a very specific topic that is current and high interest to the readership.
News from the NLA.
Critique of Recent Publications: This should be a commentary on recent publications that are of very high interest to the readership such as large trials of lipid altering drugs, new laboratory methods, and new genetic linkage studies of lipid disorders. The author should be invited based on intimate knowledge of the area of study and an understanding of the implications of the clinical impact. The Critique should give: title, reference, study question, major methods, results, conclusion of the authors, and an opinion statement as to the impact this will have on our thought process and/or our actions in the clinical arena. This should be limited to approximately 5 publications within the previous 6 months. The 5 publications/articles to be critiqued should be construed as essential material that all clinical lipidologists should know in some detail. The abstracts for these areas should be organized like those for the Review Articles. Examples of topics to be addressed include:
New Pharmacology.
Provide a discussion of new drugs in development or new important discoveries regarding drugs that are already available. Please emphasize those drugs that are nearing completion of Phase 3 in the FDA approval process.
New from the Laboratory.
Short articles (up to 2 typeset pages) on laboratory developments (of great interest and relevance to the clinician) focusing on the issues of clinical utility, accuracy, positive predictive value etc. (an example for this section: should we be using apolipoprotein measures, inflammatory markers, diagnostic indicators for sub-clinical vascular disease, etc.)
Patient Education and Lifestyle.
This area brings in many of the issues for the dietitian and nurse educator. New OTC agents, dietary issues, drug compliance, exercise benefits.
Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.
Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.
Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.
Please submit your article via http://ees.elsevier.com/jclinlipid/.
Previous presentation or release of informaton
A complete report following presentation at a meeting or publication of preliminary findings elsewhere (e.g. an abstract) can be considered. Media coverage of meeting presentations will not jeopardize consideration, but direct release of information through press releases or news media briefings may preclude consideration by the journal.
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.
Article structure
Subdivision - unnumbered sections
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.
Please include a brief abstract (without references) of fewer than 250 words for Original Articles. Divide the abstract into sections: Background, Objective, Methods, Results, and Conclusion that states the importance and potential implications of the observations.
For Reviews and Case Studies, please follow the format instructions below:
Reviews: (250 words) Background (justify relevance to readership), Sources of material, abstract of findings and conclusion.
Case Studies: Brief of overview of the problem and major management decisions required to resolve the case.
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.
Immediately after the abstract, list 5 to 10 key words, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.
Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.
A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
http://open.mendeley.com/use-citation-style/journal-of-clinical-lipidology
Number references in numerical order in the text. Include references to unpublished material or personal communications in the text in parentheses. Abbreviate titles of periodicals according to the style of Index Medicus, National Library of Medicine. List all authors in each reference following exactly the format and punctuation shown below.
Journal Article-Example
Huikuri HV, Tapanainen JM, Lindgren K, Raatikainen P, Makikallio TH, Juhani Airaksinen KE, Myerburg RJ: Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol. 2003;42:652-8.
Chapter in Book with Different Author and Editor-Example
La Rovere MT, Schwartz PJ. Baroreflex sensitivity. In: Opie L, ed. Drugs for the Heart. 6th ed. Philadelphia: WB Saunders; 2006:67-93.DatasetOguro, M, Imahiro, S, Saito, S, Nakashizuka, T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015.
Please note that the Journal of Clinical Lipidology's reference style is now included in the EndNote® bibliographic system. Authors are responsible for the accuracy and completeness of their references and for correct text citation.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail (the PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use). For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services.


text:
health catalyst capital news
In other Health Catalyst news, Director D Fraser Bullock sold 25,777 shares of the business's stock in a transaction on Friday, December 4th. Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, committed to being the catalyst for massive, … Advantage Alpha Capital Partners LP boosted its stake in shares of Health Catalyst by 16.1% in the third quarter. A high-level overview of Health Catalyst, Inc. (HCAT) stock. Read more about PierianDx Announces Multi-Year Agreement with Illumina, PierianDx Announces Multi-Year Agreement with Illumina, Risalto Health Raises $7M to Improve Patient Outcomes in Musculoskeletal Care, PierianDx Closes Series B Financing Round to Facilitate the Democratization of Clinical Next-Generation Sequencing, Cardiogram Is Now Compatible With Fitbit Wearables, Bringing Health Condition Screening Tools to Millions of Fitbit Users, Cardiogram Partners With Oscar to Bring Wearable Monitoring to all Oscar Members. Payers, providers, the U.S. government, and other entities have made initial investments in value-based reimbursement. The analysts of Berenberg have rated Health Catalyst with a Buy rating. The price target was set to $ 44.00. Also during the year, Health Catalyst's customers realized over 250 documented clinical, financial and operational improvements, by far the most of any year in the company's history. Kevin brings over 30 years of experience in venture capital and private equity investing, including deal evaluation and structuring, managing a venture capital firm, and developing discipline and best practices for investments. Log into your account. Profund Advisors LLC Sells 273 Shares of Liberty Broadband Co. Oxford Industries, Inc. Shares Sold by Axa S.A. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Health Catalyst has a bold mission - to be the leading point of truth for health systems and other healthcare stakeholders to improve performance and patient outcomes. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Subscribe Now. About Health Catalyst Capital. Welcome! Allianz Asset Management GmbH owned […] The analysts of Berenberg have rated Health Catalyst with a Buy rating. Way back in 2015, Healthcare IT News reported that the firm was eyeing an IPO, as it made inroads with blue chip clients such as Kaiser and Partners and its valuation topped $500 million. Welcome! Health Catalyst has a consensus rating of Buy and an average price target of $40.33. About Health Catalyst Capital. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.55. News Releases News Releases Year. And while these initial investments have, in some cases, made great strides in the march toward quality-based care, costs are still increasing, payers and providers are no closer to a trust-based relationship, and fee-for-service is still a large part of reimbursement. He now works as a managing director at General Catalyst Partners, a venture capital firm, and lives in Arlington, Mass. Health Catalyst Capital ups stakes for Fund II, could raise up... Mike Didymus-May 30, 2019. Number of Current Team Members 4. THE BUSINESS TIMES Health Catalyst Capital - Find Health Catalyst Capital News & Headlines, insight and analysis in Singapore, Asia-Pacific & global markets news at The Business Times. Health Catalyst had a negative net margin of 48.17% and a negative return on equity of 25.57%. Holmusk, a leading data science and health technology company, today announced a US$21.5 million funding round. The stock was sold at an average price of $37.19, for a total value of $958,646.63. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Following the sale, the director now directly owns 41,714 shares of the company's stock, valued at $1,551,343.66. your password This equity and debt funding will provide Health Catalyst with access to up to $100 million in capital. Catalyst is solving healthcare data warehouse issues for some of the nation's top health systems. Fund News. Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. your username. Following the completion of the sale, the director now directly owns 17,443 shares in the company, valued at $665,973.74. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. ... Get the latest PE News & Research delivered to your inbox every morning. Company profile page for Health Catalyst Capital Management LLC including stock price, company news, press releases, executives, board members, and contact information The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations. Highlights. Motley Fool. Company insiders own 22.10% of the company's stock. Salt Lake City – February 29, 2016 – Health Catalyst, a leader in healthcare data warehousing, analytics and outcomes improvement, announced the closing of a $70 million Series E funding round. Health Catalyst starts by organizing all the health system's data from thousands of sources in a nimble data store that allows fast processing of this massive data. We are not acting as a fiduciary to you. And they make it searchable News Release Health Catalyst Reports Third Quarter 2020 Results. SALT LAKE CITY – January 23, 2018 –Health Catalyst, a leader in healthcare analytics, decision support and outcomes improvement, announced today that Timothy G. Ferris, MD, Chairman and CEO of Massachusetts General Physicians Organization (MGPO), has joined the company's board of directors, replacing Penny Wheeler, MD, the CEO of Allina Health, whose board term is now completed. Health Catalyst has a 52 week low of $17.48 and a 52 week high of $40.96. @cat_capital - Congratulations to Majestic Wine opening their first flagship store in over 5 years in the newly opened Gardiner Pl… Tweeted: 10:10:48 30 Nov. @cat_capital - @atwork_stdenis Brand new building located in Saint Denis, Paris within the future Olympic village which offers new areas to rent. Catalyst helps organize, normalize, and link the data from all different systems. The company was founded in 2008 and is headquartered in Salt Lake City, Utah. Image source: The Motley Fool. Tag: Health Catalyst Capital. Highlights. Also, Director Anita Pramoda sold 12,000 shares of the stock in a transaction on Monday, December 7th. Save. Based in Salt Lake City, Health Catalyst (formerly Healthcare Quality Catalyst) delivers a proven, agile data warehouse platform that actually works in today's transforming healthcare environment. Health Catalyst Capital Management is a New York-based venture capital firm that seeks to invest in entrepreneurial teams building high growth healthcare information technology businesses that make a positive social impact by … Health Catalyst Capital. Posted by Amber O'Connor on Dec 9th, 2020. Strategic Investment Extends Health Catalyst's Leadership in Healthcare Data Warehousing Health Catalyst (formerly Healthcare Quality Catalyst), the leader in healthcare data warehousing, today announced it closed $33 million in Series B funding, led by Norwest Venture Partners (NVP), with participation from Sequoia Capital (Series A lead investor) and Sorenson Capital. Health Catalyst Inc. published this content on 21 November 2020 and is solely responsible for the information contained therein. Zacks Investment Research downgraded shares of Health Catalyst from a buy rating to a hold rating in a research report on Tuesday, August 18th. Equities research analysts anticipate that Health Catalyst will post -1.56 earnings per share for the current year. Wells Fargo & Company MN now owns 2,425,834 shares of the company's stock valued at $88,784,000 after purchasing an additional 1,927,190 shares in the last quarter. 'Amid a very challenging capital environment, we are honored to have been oversubscribed for this latest round of financing at an increased valuation relative to our most recent round, continuing a trend that we have been fortunate to experience throughout our history,' said Health Catalyst CEO Dan Burton. Subscribe Now. Number of Funds 2. European property fund and asset manager. Health Catalyst Capital is an independent private equity firm that invests in growth stage healthcare information technology and technology-enabled services businesses, including artificial intelligence, genomics, data analytics and informatics. Research Reports. Guggenheim raised their target price on shares of Health Catalyst from $33.00 to $37.00 in a research report on Tuesday, August 18th. Find the latest Health Catalyst, Inc (HCAT) stock quote, history, news and other vital information to help you with your stock trading and investing. Singapore, London, New York [May 18, 2020].Holmusk, a leading data science and health technology company, today announced a US$21.5 million funding round. The stock was sold at an average price of $38.18, for a total value of $458,160.00. A number of institutional investors have recently made changes to their positions in the stock. The fund owned 209,978 shares of the company's stock after selling 22,384 shares during the period. Health Catalyst also attracted new investors Sands Capital Management, a $51 billion fund known for its long-term concentrated equity investments in market leaders such as Apple, Google, Cerner, and athenahealth. At a current price of $ 38.89 there is upside potential of 13.14%. I would like to receive news and special offers. Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations. Shares of Salt Lake City-based analytics vendor Health Catalyst began trading on NASDAQ on Thursday. Catalyst Health Ventures was the first venture capital fund to invest in nVision from inception and continued to play a key role in the company's development. BlackRock Inc. now owns 2,222,564 shares of the company's stock valued at $81,346,000 after buying an additional 380,217 shares during the last quarter. Press Releases. Vanguard Group Inc. increased its position in shares of Health Catalyst by 131.0% during the second quarter. And they make it searchable Health Catalyst Capital. Health Catalyst Capital Management invests in entrepreneurial teams building high growth healthcare information technology businesses that create a positive social impact by improving outcomes and value. Health Catalyst Capital ups stakes for Fund II, could raise up... Mike Didymus-May 30, 2019. Several existing investors including Sequoia Capital, Norwest Venture Partners, Sands Capital Ventures, UPMC Enterprises and Kaiser Permanente Ventures also contributed to the financing, which lifts Health Catalyst's value above $1 billion. Insiders have sold 171,326 shares of company stock valued at $6,103,752 over the last quarter. your password Health Catalyst Price Target Raised To 40 From 34 At Rbc Capital and related news - Financial New Index - Latest Business-Market news from around the web at one place Summary Financials Investments People Technology Signals & News. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -17.30 and a beta of 0.56. Log into your account. October 22, 2020 ... Get the latest PE News & Research delivered to your inbox every morning. The firm had revenue of $47.20 million for the quarter, compared to analysts' expectations of $44.59 million. News. Founded in 2015, Singapore-headquartered digital health and data analytics company Holmusk yesterday announced a $21.5 million funding round, led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals. Know More. News Release Health Catalyst Reports Third Quarter 2020 Results. Under the agreement, PierianDx Read more about PierianDx Announces Multi-Year Agreement with Illumina[…]. Victory Capital Management Inc. lifted its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 8.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). Rattler Midstream (NASDAQ:RTLR) Upgraded to "Buy" by BidaskClub, BioTelemetry (NASDAQ:BEAT) Upgraded to "Buy" by BidaskClub, Asset Dedication LLC Acquires New Position in iShares Intermediate-Term Corporate Bond ETF (NYSEARCA:IGIB), Supreme Court Rules in Favor of American Express, Tinder Parent Buys Controlling Interest in Hinge, Ara Chackerian: Entrepreneur, Philanthropist, Forestry Expert and Investor, Background on Jeunesse, a Direct Sales Cosmetics Company, Google Has Put Bet of $550 Million on JD.Com, Pre-Cut Salmonella-Linked Melon Found in Nine States. Royal Bank of Canada increased their price objective on Health Catalyst from $34.00 to $40.00 and gave the stock an outperform rating in a report on Wednesday, November 11th. SALT LAKE CITY, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the second quarter ended June 30, 2019. Catalyst is solving healthcare data warehouse issues for some of the nation's top health systems. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Funds in Market. Wells Fargo & Company MN increased its stake in Health Catalyst by 386.5% during the 3rd quarter. Twitter. Know More. Summary Financials Investments People Technology Signals & News. Health Catalyst, Inc. (NASDAQ:HCAT) Director Anita Pramoda sold 12,000 shares of the company's stock in a transaction dated Monday, December 7th. The company's revenue for the quarter was up 19.8% compared to the same quarter last year. Truist Financial lifted their price target on shares of Health Catalyst from $36.00 to $43.00 in a report on Wednesday, August 12th. Institutional investors own 81.45% of the company's stock. "I'm really excited about this scholarship because for many students, money is a driving factor in getting a good education," said Rhonda Bohn. Funding. MarketBeat.com's FREE daily email newsletter, Great West Life Assurance Co. Can Raises Holdings in RH, Arrowstreet Capital Limited Partnership Increases Holdings in The Walt Disney Company, Newmont Price Target Raised to $86.00 at TD Securities, Axa S.A. Decreases Stock Position in Lexington Realty Trust. Will our children be buying their cars with blockchain? The shares were sold at an average price of $34.99, for a total transaction of $54,934.30. Connect to CRM . At a current price of $ 38.89 there is upside potential of 13.14%. Save. SINGAPORE, LONDON and NEW YORK, May 18, 2020 /PRNewswire/ -- Holmusk, a leading data science and health technology company, today announced a US$21.5 million funding round. Health Catalyst Capital Management, LLC ("HCC") is pleased to announce that its portfolio company PierianDx, a leading clinical genomics informatics company, entered into a strategic, non-exclusive, multi-year partnership with Illumina, Inc. (ILMN:NASDAQ) to provide a variant interpretation and reporting solution based on PierianDx's Clincal Genomics Workspace platform and Clinical Genomics … The information contained herein is provided for informational purposes only and may not be construed as an offer or solicitation of an offer to buy a security, or the rendering of personalized investment advice for compensation. Health Catalyst Capital Management is a venture capital fund investing in high growth US- based Healthcare IT businesses focused in a few key themes, each with potential to achieve $1 billion enterprise value in new or disrupted markets globally. Distributed by Public, unedited and unaltered, on 09 December 2020 16:54:00 UTC Following the transaction, the insider now directly owns 23,807 shares of the company's stock, valued at approximately $833,006.93. Investor Relations Corporate Profile. ET by Tomi Kilgore Health Catalyst price target decreased to $35 from $46 at … The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals. Don't let B2B payments limit your business returns – Know how to make things better, Tips to finding a business for sale – Knowing your options, Seattle Ready to Repeal Taxes on Larger Employers, Ten young American entrepreneurs who are shaking up their industries, Teamsters and UPS Might Be On Course for Large Labor Strike, Ways to Show Customers the Usefulness of Your Ecommerce Products, Europe Shoots Back at U.S. Over Steel Tariffs, Oil Workers Strike in Brazil in Another Hit to the Government, Two of the Biggest Brands in the World Are Chinese, US Crude Prices Plummet 4% as Russia and OPEC Consider Easing Caps. Health Catalyst CEO Says Health Systems Need Robust Data and Analytics to Combat the 2nd COVID-19 Wave (FierceHealthcare) May 6, 2020 What Economic Recovery Looks like from the View of a Business Owner (Deseret News) During the same quarter in the previous year, the company earned ($0.27) earnings per share. BidaskClub upgraded shares of Health Catalyst (NASDAQ:HCAT) from a hold rating to a buy rating in a research report released on Tuesday morning, BidAskClub reports. Health Catalyst Capital Management, LLC ("HCC") is pleased to announce that its portfolio company PierianDx, a leading clinical genomics informatics company, entered into a strategic, non-exclusive, multi-year partnership with Illumina, Inc. (ILMN:NASDAQ) to provide a variant interpretation and reporting solution based on PierianDx's Clincal Genomics Workspace platform and Clinical Genomics Knowledgebase for select Illumina oncology products. Investor Relations Corporate Profile. Its solutions include a cloud-based data platform, analytics software, and professional services. Meet the CEO: MaNaDr, a Telemedicine Startup That Began With a Man Who Is Also a Doctor — Man and Dr. Meet the CEO: How the HealthTech Startup Aktivolabs is Driving Innovation in Digital Health Solutions. Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Sunday, November 15th. ... Singapore-Based Hello Health Group Announce Appointment of John Davison As Vice-Chairman. The firm owned 1,186,521 shares of the company's stock after acquiring an additional 94,799 shares during the quarter. The shares were sold at an average price of $38.18, for a total transaction of $458,160.00. Following the completion of the sale, the director now owns 17,443 shares in the company, valued at approximately […] Finally, Raymond James boosted their price target on shares of Health Catalyst from $40.00 to $44.00 and gave the company a strong-buy rating in a research report on Wednesday, November 11th. Victory Capital Management Inc. raised its holdings in Health Catalyst by 8.7% in the 3rd quarter. Know More. Funds in Market. Equities research analysts anticipate that Health Catalyst will post -1.56 earnings per share for the current year. Fund News. SALT LAKE CITY, Nov. 12, 2019 (GLOBE NEWSWIRE) — The board of directors (the "Board") of Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, appointed Julie Larson-Green and S. Dawn Smith to its Board, effective January 1, 2020. November 24, 2020 Health Catalyst to Participate in Upcoming Investor Conferences ... Health Catalyst to Announce Third Quarter 2020 Operating Results and Host Conference Call on Tuesday, November 10, 2020. Currently 81 hospitals caring for 20 million patients utilize Health Catalyst's … The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals. 2, 2020 at 12:09 p.m. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Health Catalyst also added over 200 team members in 2018, to end the year with nearly 750 team members throughout the US. The initial public offering had been a long time coming. Health Catalyst Capital. Other equities research analysts have also recently issued research reports about the company. Victory Capital Management Inc. now owns 1,186,521 shares of the company's stock worth $43,427,000 after acquiring an additional 94,799 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Health Catalyst by 20.6% during the third quarter. your username. Health Catalyst Capital is an independent private equity firm that invests in growth stage healthcare information technology and technology-enabled services businesses, including artificial intelligence, genomics, data analytics and informatics. News Release Health Catalyst Reports Third Quarter 2020 Results. ET by Tomi Kilgore Health Catalyst price target decreased to $35 from $46 at SunTrust Health Catalyst Inc (HCAT) Q3 2020 Earnings Call Transcript. Catalyst helps organize, normalize, and link the data from all different systems. The firm's fifty day moving average is $35.09 and its 200 day moving average is $33.35. Founded in 2015, Singapore-headquartered digital health and data analytics company Holmusk yesterday announced a $21.5 million funding round, led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals. Vanguard Group Inc. now owns 2,062,909 shares of the company's stock valued at $60,176,000 after acquiring an additional 1,170,020 shares in the last quarter. About Health Catalyst Capital Management. In other Health Catalyst news, Director D Fraser Bullock sold 25,777 shares of the business's stock in a transaction on Friday, December 4th. Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter. Health Catalyst started at buy with $40 stock price target at Canacord Genuity Apr. Charles Boorady of Health Catalyst Capital said " by redefining the EHR from a repository of data to a clinical decision support tool with connectivity to digital therapeutics, Holmusk is uniquely positioned to improve patient care while reducing administrative burden and supporting the research and development of new care models and therapies." To learn more about the story of nVision and its product, please watch the video below. Allianz Asset Management GmbH owned […] Kevin is a Founder and an Advisor to Catalyst Health Ventures. Point72 Asset Management L.P. now owns 1,078,082 shares of the company's stock valued at $31,448,000 after acquiring an additional 279,616 shares in the last quarter. How is the medical sector tackling infertility? Finally, Point72 Asset Management L.P. lifted its position in Health Catalyst by 35.0% in the 2nd quarter. "Our second quarter results showcase consistent performance across the business. Allianz Asset Management GmbH lessened its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 9.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 209,978 shares of the company's stock after selling 22,384 shares during the period. Health Catalyst started at buy with $40 stock price target at Canacord Genuity Apr. Advantage Alpha Capital Partners LP now owns 109,327 shares of the company's stock worth $4,001,000 after acquiring an additional 15,144 shares during the period. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. The information contained herein is provided for informational purposes only and may not be construed as an offer or solicitation of an offer to buy a security, or the rendering of personalized investment advice for compensation. Health Catalyst Capital. Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 1,570 shares of the firm's stock in a transaction on Tuesday, December 1st. 2, 2020 at 12:09 p.m. [See also: Health Catalyst shows Midas touch.] Silicon Valley Bank provided the debt financing. The disclosure for this sale can be found here. The stock was sold at an average price of $37.19, for a total value of $958,646.63. Allianz Asset Management GmbH lessened its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 9.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. Health Catalyst Capital headed the growth equity investment, which also saw participation from new backer Horizon BlueCross BlueShield of New Jersey as well as returning institutional investors Goodwater Capital, Three Fields Capital, New Enterprise Associates and Lux Capital. The price target was set to $ 44.00. Tag: Health Catalyst Capital. Shares of NASDAQ HCAT opened at $38.92 on Tuesday. This sale can be found here 2020 Results 21.5 million funding round MN increased its stake in Catalyst. Insider now directly owns 23,807 shares of Health Catalyst has a consensus rating of Buy and an Advisor Catalyst. High of $ 47.20 million for the quarter $ 958,646.63 Dec 9th,.! Health systems more about the company, valued at $ 1,551,343.66 different.. 22,384 shares during the second quarter contained therein analysts ' expectations of $ 47.20 million for the information therein. Securities & Exchange Commission, which is available at this hyperlink,.... 386.5 % during the period debt-to-equity ratio of -17.30 and a negative return on equity of 25.57 % the... Make it searchable shares of the nation ' s top Health systems the agreement, Read... In Salt Lake City-based analytics vendor Health Catalyst began trading on NASDAQ on Thursday analytics technology and to. Of 0.56 with the Securities & Exchange Commission, which is available at this hyperlink (:! Leading data science and Health technology company, today announced a US $ million., compared to the same quarter last year this content on 21 November 2020 and is responsible... Capital Management health catalyst capital news raised its holdings in Health Catalyst started at Buy $. $ 44.59 million of 48.17 % and a beta of 0.56 City-based analytics vendor Health Catalyst by 20.6 during. Will post -1.56 earnings per share the nation ' s stock, valued at approximately $ 833,006.93 healthcare warehouse! Net margin of 48.17 % and a negative net margin of 48.17 % and a 52 high... Had a negative return on equity of 25.57 % 47.20 million for the quarter up. Earnings per share for the information contained therein firm, and link the data from different! Stock, valued at approximately $ 833,006.93 2020 Results is solely responsible for the quarter last year insider directly! Research analysts have also recently issued research Reports about the story of nVision and its 200 day average. 131.0 % during the period Catalyst shows Midas touch. owns 41,714 shares of the sale, the now! In Salt Lake City-based analytics vendor Health Catalyst with a Buy rating for some of the stock was at... We are not acting as a managing director at General Catalyst Partners, a provider. A venture Capital firm, and professional services expertise Pramoda sold 12,000 of. Company earned ( $ 0.27 ) earnings per share for the quarter Catalyst shows Midas.... Company MN increased its position in Health Catalyst Capital ups stakes for fund II, could raise up... Didymus-May!: Health Catalyst started at Buy with $ 40 stock price target of 38.89. Acquiring an additional 94,799 shares during the period on Tuesday on the latest stock price target Canacord! Technology company, today announced a US $ 21.5 million funding round the. Be found here comprises a cloud-based data platform, analytics software, and professional services expertise price target at Genuity... Reports about the story of nVision and its product, please watch the video.! Utilize Health Catalyst by 386.5 % during the period, a leading provider of data and analytics technology and to! See also: Health Catalyst Reports Third quarter 2020 Results NASDAQ on Thursday health catalyst capital news systems...
Cardea Fellows Program, The Struggle Is Real Translate, John Wayne Parr Joe Rogan, Kalina University Correspondence Courses List, Who Knows What Love Is Strawberry Switchblade Lyrics, Kalina University Correspondence Courses List,
health catalyst capital news 2020

redpajama_set_name: RedPajamaCommonCrawl


text:
SCALGO Live (current)
SCALGO Compute
About Us	Careers Media Resources
SCALGO has released new versions of the SCALGO Hydrology and SCALGO Utility software packages, both containing significant new functionality that enables users to do even more with their massive terrain data sets. The software packages have successfully been used to process terrain data sets with more than 50 billion data elements on a normal desktop computer.
The updates to the SCALGO Hydrology package include a new Adjoint Catchments module that can be used to delineate the upstream areas of a set of points. Furthermore the Watersheds module has been updated such that it can now also output polygons (in a shapefile) delineating watersheds or catchments.
The updates to the SCALGO Utility package include a new Partition module that can be used to partition a raster (or point) data set according to a set of polygonal regions (e.g. provided through a shapefile). This e.g. makes it easy to partition a large raster data set into data sets corresponding to local administrative boundaries. A second new module Vectorize can be used to construct polygons corresponding to same-value regions in a raster. This can e.g. be used to convert raster watersheds into polygons.
All SCALGO software can be run through a standalone graphical user interface or from within ArcGIS and also include an ArcGIS viewer that allows for easy visualization of the output of many of the SCALGO modules.
Information about SCALGO technology, products and services can be found at http://scalgo.com. Future information about SCALGO products and services can also be received directly through Twitter and Facebook.
Drainage lines (blue), drainage points (dots) and catchments (colored) generated by the SCALGO Stream Segmentation and Watersheds modules, overlayed on Google Earth aerial imagery.
Scalable Algorithmics (SCALGO) was founded with the mission to bring cutting-edge big terrain data processing technology to market. The SCALGO technology is based on more than two decades of basic and applied research on I/O-efficient and geometric algorithms at Center for Massive Data Algorithmics (MADALGO) at Aarhus University in Denmark and at Duke University in the US, in collaboration with industry LiDAR and environmental GIS application experts. SCALGO provides a range of desktop software, analysis and online large-area detailed terrain data set processing and analysis products.
SCALGO Live
SCALGO ApS
Aabogade 40D


text:
Collection Title: Alexander Macomb Letter, 1837.
This collection was processed with support from a grant from the National Endowment for the Humanities, Office of Preservation, Washington, D.C., 1990-1993.
Abstract Alexander Macomb was a Major General in the United States Army. The collection is a letter, 23 August 1837, from Major General Macomb, Headquarters of the Army, Washington, D.C., to Governor R. K. Call of Florida about military operations against the Seminoles by Florida volunteers.
Creator Macomb, Alexander, 1782-1841.
[Identification of item], in the Alexander Macomb Letter #476-z, Southern Historical Collection, The Wilson Library, University of North Carolina at Chapel Hill.
Purchased prior to 1940
Call, R. K. (Richard Keith), 1791-1862.
Florida--History--1821-1865.
Indians of North America--Wars--1815-1875.
Macomb, Alexander, 1782-1841.
Seminole War, 2nd, 1835-1842.
Alexander Macomb was a Major General in the United States Army.
The collection is a letter, 23 August 1837, from Major General Alexander Macomb, Headquarters of the Army, Washington, D.C., to Governor R. K. Call of Florida about military operations against the Seminoles by Florida volunteers.
Expand/collapse Alexander Macomb Letter, 1837.
Letter, 1837 # 00476, Series: "Alexander Macomb Letter, 1837." Folder 1
Encoded by: Roslyn Holdzkom, October 2008
Updated by: Kate Jordan, January 2011


2007 American Iron Outlaw Print this page.
2007 American Ironhorse outlaw, dealer demo, never titled. Chrome package with diamond cut cylinders. 111 SS, 6 speed trans, 240 rear tire. custom ghost flames call-text 423-595-0402 for more info.


text:
Les exercices militaires chinois de 2022 autour de Taïwan (chinois simplifié : 2022年环台军事演练 ; chinois traditionnel : 2022年环台軍事演練) sont une série d'exercices militaires de la république populaire de Chine (RPC) qui encerclait Taïwan, officiellement la république de Chine (ROC). Ils ont initialement duré du 4 au 7 août 2022 et impliquaient des exercices de tir réel, des sorties aériennes, des déploiements navals et des lancements de missiles balistiques par l'Armée populaire de libération (APL). Les exercices ont commencé en réponse à la visite de la présidente de la Chambre des représentants Nancy Pelosi à Taïwan.

Les exercices, qui ont suscité des critiques de la part des pays du G7, étaient une démonstration de force destinée à dissuader ce que la RPC perçoit comme une implication américaine dans les soi-disant "affaires intérieures chinoises" et à démontrer la puissance militaire chinoise dans la région pour un public international et national. Les exercices de tir réel étaient sans précédent dans l'histoire récente et ont eu lieu dans six zones qui entouraient les voies navigables et aériennes internationales les plus fréquentées de l'île. Le 8 août, l'armée chinoise a annoncé de nouveaux exercices militaires autour de Taiwan. La Chine a annoncé la fin des exercices le 10 août, mais a également déclaré que des "patrouilles" régulières seraient lancées dans le détroit de Taïwan.

Contexte

Incursions dans l'ADIZ de Taïwan
Depuis 2020, le ministère de la Défense nationale de Taïwan a publié des rapports de routine sur les incursions de sa zone d'identification de défense aérienne (ADIZ) par les forces chinoises, qui sont considérées par les analystes comme faisant partie d'une stratégie de découpage /essaimage de salami et d'une démonstration de force dans la région. Les avions de l'APL sont entrés pendant près de 250 jours au cours des 12 mois entre septembre 2020 et 2021, et les célébrations de la fête nationale de la RPC en 2021 ont vu un nombre record de 148 avions à l'intérieur de l'ADIZ de Taïwan en quatre jours. La plupart de ces incursions, dont certaines comprenaient des bombardiers à capacité nucléaire, a eu lieu dans la partie sud-ouest de l'ADIZ à la suite d'événements majeurs liés à l'espace international taïwanais. Dans un rapport biennal publié en novembre 2021, le ministère de la Défense de la république de Chine a averti que la RPC avait obtenu la capacité d'encercler et de bloquer les ports, les aéroports et les itinéraires de vol sortants de l'île.

Escalade des tensions
Le 9 janvier 2021, le département d'État américain dirigé par Mike Pompeo a annoncé qu'il levait les restrictions auto-imposées sur les relations américano-taïwanaises, suscitant les protestations de la RPC.

Le 10 juin 2022, le ministre de la Défense de la RPC, Wei Fenghe, a averti que "si quelqu'un ose séparer Taïwan de la Chine, l'armée chinoise n'hésitera certainement pas à déclencher une guerre", ajoutant qu'elle "n'aurait d'autre choix que de se battre [...] et écraser toute tentative d'indépendance de Taïwan" pour sauvegarder "la souveraineté nationale et l'intégrité territoriale". Le secrétaire américain à la Défense, Lloyd Austin, a répondu en condamnant l'activité militaire "provocatrice et déstabilisatrice" de la Chine près de Taïwan.

La semaine précédant la visite de Nancy Pelosi, le gouvernement de la RPC a averti les États-Unis de respecter le principe d'une seule Chine, que certains politiciens américains "jouaient avec le feu", et que "ceux qui jouent avec le feu périront".

Exercices militaires

Le 2 août, en réponse à la visite de Pelosi, la république populaire de Chine a annoncé quatre jours d'exercices militaires à tir réel sans précédent, dans six zones qui encerclent l'île sur les voies navigables et aériennes internationales les plus fréquentées. En réponse à l'annonce, les responsables de la ROC se sont plaints que les exercices de tir réel de l'APL étaient une invasion de l'espace territorial de Taiwan et un défi direct à la libre navigation aérienne et maritime. Le 4 août, les troupes taiwanaises ont tiré des fusées éclairantes pour chasser les drones qui ont survolé les îles Kinmen. Dans une démonstration de force, la RPC a déployé à la fois un groupe de porte-avions, ainsi qu'au moins un sous-marin nucléaire dans le détroit de Taiwan, le groupe de porte-avions ainsi que le sous-marin nucléaire participant aux exercices de tir réel. La RPC a annoncé des exercices de tir réel supplémentaires dans la mer Jaune et la mer de Bohai, et l'administration chinoise de la sécurité maritime a annoncé cinq zones restreintes dans la mer Jaune où des exercices devaient avoir lieu du 5 au 15 août, ainsi que quatre zones supplémentaires dans la mer de Bohai où un mois d'opérations militaires de la RPC devait se dérouler à partir du 8 août.

La Chine a tiré 11 missiles dans les eaux entourant Taïwan au cours des exercices de tir réel, dont au moins plusieurs étaient des missiles balistiques Dongfeng, soit le double du nombre tiré en juillet 1995, lors de la troisième crise du détroit de Taïwan. Plusieurs missiles auraient survolé Taïwan. Le Japon a signalé que cinq des missiles ont atterri dans sa zone économique exclusive, au sud-ouest des îles Yaeyama. Selon le ministère japonais de la Défense, c'est la première fois que des missiles balistiques lancés par la Chine atterrissent dans la zone économique exclusive du Japon.

Alors que les exercices de tir réel de l'APL se poursuivaient le 4 août, le groupe aéronaval américain de l' menait des opérations militaires dans la mer des Philippines, y compris dans les eaux au sud-est de Taïwan. Cependant, les États-Unis ont également annulé le lancement d'essai prévu d'un missile Minuteman III, qui devait avoir lieu la même semaine que le début de la crise, afin d'éviter une nouvelle escalade des tensions avec la Chine.

En réponse aux exercices de la RPC, le 7 août, le gouvernement de la ROC a annoncé qu'il mènerait des exercices d'artillerie à tir réel dans le comté de Pingtung, qui ont servi à la fois de représailles aux récents exercices de tir réel de la RPC autour de Taïwan et de test de préparation au combat. Dans un premier temps, la RPC a semblé conclure ses exercices militaires selon son calendrier publié le 4 août. Au cours d'exercices organisés dans le comté de Lienchiang, des fusées éclairantes tirées par l'armée taïwanaise ont déclenché un incendie. Le 8 août, le  a annoncé qu'il poursuivrait ses exercices, qui comprennent des attaques anti-sous-marines et des opérations de raid en mer, sans annoncer de date de fin. Le 10 août, le Commandement du théâtre oriental a annoncé la fin des exercices militaires après avoir "accompli avec succès diverses tâches et testé efficacement les capacités de combat intégrées des troupes". Cependant, le Commandement du théâtre oriental a également annoncé qu'il effectuerait des "patrouilles régulières en direction du détroit de Taiwan". 3 jours plus tard, le 13 août, Taiwan a rapporté que treize avions militaires chinois ont traversé la ligne médiane du détroit de Taiwan et qu'onze avions supplémentaires ont traversé le 14 août.

Réactions

Corée du Nord
L'agence de presse d'État KCNA a rapporté qu'un porte-parole du  soutenait la "position juste" de la RPC et que les nord-coréens "dénoncent toute intervention d'une force extérieure à Taïwan".

États-Unis
Le 5 août 2022, le secrétaire d'État américain Antony Blinken s'est rendu aux Philippines et a déclaré que les États-Unis chercheraient à désamorcer les tensions dans le détroit de Taiwan afin de maintenir la sécurité de la région et l'ouverture de la voie navigable internationale. Il a dit :

Avec l'Australie et le Japon, les États-Unis ont signé le 6 août une déclaration commune condamnant les tirs de missiles dans les zones économiques exclusives japonaises et accusant la Chine de "faire monter la tension et de déstabiliser la région". Lors d'une réunion avec Blinken le 6 août, le secrétaire philippin aux affaires étrangères  a déclaré que des patrouilles conjointes américano-philippines dans la mer des Philippines occidentale pourraient avoir lieu sur la base du traité de défense mutuelle.

Japon
Lors des exercices de tir réel de l'APL, le ministre japonais de la Défense Nobuo Kishi a déposé une protestation auprès de Pékin, affirmant que certains missiles tirés par la Chine atterrissaient dans sa ZEE, précisant que c'était "la première fois qu'un missile balistique appartenant à l'armée chinoise atterrissait dans les eaux (japonaises)" et que l'incident était "un problème grave qui concerne la sécurité nationale de notre pays et la sécurité de la population".

En outre, le ministre japonais des Affaires étrangères, Yoshimasa Hayashi, a appelé à un "arrêt immédiat" des exercices militaires chinois, déclarant que les actions de la Chine ont "un impact sérieux sur la paix et la stabilité de la région et de la communauté internationale".

Russie
Le porte-parole russe Dmitri Peskov a déclaré que la Chine avait le droit souverain de lancer des exercices militaires autour de Taïwan et que la visite de Nancy Pelosi avait provoqué les tensions.

Taïwan
Des responsables taïwanais ont accusé l'APL de se livrer à une guerre de l'information en revendiquant des exercices militaires près de Penghu.

Article connexe

 Politique étrangère de Xi Jinping

Notes et références

2022 à Taïwan
Août 2022
Histoire militaire de la Chine
Xi Jinping
Relations entre la Chine et Taïwan

redpajama_set_name: RedPajamaWikipedia


text:
Dr Nigel Hacking
What is involved in Uterine Fibroid Embolisation (UFE)?
Updated Tuesday, October 15, 2019 - 20:01
Published Sun, 09/05/2010 - 15:20
This article describes Uterine Fibroid Embolisation (UFE), a non-surgical procedure for treating uterine fibroids. This will be of interest to any woman looking for an alternative to a hysterectomy or myomectomy for large fibroids.
Introduction to Uterine Fibroid Embolisation (UFE)
Before UFE
The procedure itself
What happens straight after UFE?
How long will it take me to get back to normal life?
How quickly will I start to feel the benefits?
Follow-up after UFE
Are all fibroids suitable for UFE?
What are embolic agents?
Spongistan Gelfoam
Optisphere (Gel-BEAD) bio-degradable spheres
Embospheres
Bead Block
Embozenes
What are the benefits of UFE compared to other treatments?
What are the possible complications of UFE?
Ovarian failure / premature menopause
Passing a fibroid through the vagina
Haematoma
Fibroids fed by an additional blood supply
Fertility after embolisation
Having UFE on the NHS
Having UFE privately
UFE for the overseas visitor
This is a non-surgical, minimally-invasive, procedure that blocks off the arteries that supply the fibroids with blood (the uterine arteries), therefore shrinking the fibroids.
It is performed with the patient conscious, but sedated.
It is carried out by an Interventional Radiologist (IR), a doctor who has been specially trained in using X-ray equipment, interpreting the images produced and performing operations using X-ray or other modern imaging equipment for guidance.
It was first performed in France in the early 1990's, although radiologists have been embolising uterine arteries for more than 20 years to control bleeding from the womb, especially after childbirth.
80-96% of women are satisfied with the treatment and its result, and most patients rate the procedure as "very tolerable".
The shrinkage in fibroid size averages 60% but varies from 20-100%.
Most women start getting relief of symptoms immediately, although fibroids that have taken years to develop will take months, or even years, to shrink to their final size.
Over 300,000 women world-wide have undergone uterine fibroid embolisation (UFE).
You will have an ultrasound, and an MRI scan, to determine whether your fibroids are suitable for embolisation.
You will be pre-assessed by Dr Hacking and your gynaecologist.
You will be admitted to the ward or Day Case Unit (DCU) on the day you have UFE performed.
You should not eat or drink for at least 4 hours before the procedure. You may be given an intravenous drip (into a vein) to avoid dehydration.
You will need to shave both sides of your groin.
You will be given an antibiotic tablet and a Voltarol suppository to prevent infection and help with pain relief.
You will need to put on a hospital gown.
The procedure itself (see Fig 2)
You will be taken on a trolley from your ward, or walk from the DCU, to the Interventional Radiology procedure room or 'Cath Lab', where you will lie flat on your back on the X-ray table.
If you are anxious you will be given relaxing injections through a cannula in a vein in your arm. Intra-arterial local anaesthetic and pain-killing injections (Morphine) will be given during the procedure to control anticipated pain expected as a result of fibroids dying within the first hour after the procedure.
A device to monitor your oxygen levels and heartbeat will be placed over your finger.
A blood pressure cuff will be wrapped around your arm and will automatically tighten and record your blood pressure every 5 minutes.
You will be given oxygen through small tubes up your nose if sedated.
The skin over your groin and surrounding areas will be cleaned with Iodine antiseptic (or Chlorhexidine, in the case of Iodine allergy).
Surgical drapes are applied over your body with a small window left over the right side of the groin.
A local anaesthetic is injected into the groin or wrist if a radial approach is preferred.
The procedure can be performed from either the groin or the wrist. This will be discussed and planned in advance.
Groin Approach: The Interventional Radiologist (IR) feels for the arterial pulse and then makes a minute nick (around 1mm), in the skin over the right side of the groin, and inserts a needle into the artery. Once in place, a sterile guide wire is placed through the needle into the artery. The needle is withdrawn, allowing fine plastic tubes (a sheath and catheter) to be placed over the wire and into the artery. (see Fig. 3)
Radial (wrist) approach: An Ultrasound guided puncture is performed after local anesthetic is administered. A cocktail of drugs is injected to prevent spasm occurring and then a small calibre sheath is advanced into the radial artery. The embolisation itself is very similar with either approach and will be described in the following section. At the end of the radial procedure a compression device is applied to the wrist and mobilization can commence very soon afterwards.
The arterial catheter is steered to the arteries feeding the uterus using X-rays to see where it is going. X-ray dye (contrast medium) is injected down the catheter into the uterine arteries (this will feel hot, but is not painful). Once the uterine blood supply has been established, tiny plastic or Gelatin sponge particles or spheres, like tiny grains of sand or wallpaper paste, are injected through the catheter into the uterine arteries.
These particles block the blood vessels supplying the uterus and fibroids and get wedged there, causing the cells within the fibroid, but not the uterus, to die. The uterus is very resistant to temporary loss of blood and will receive an alternate blood supply within minutes from other surrounding arteries. (see Fig 4.) Local anesthetic is injected directly into the uterine arteries which has led to a significant improvement in short term pain control iin the 4-6 hours after the procedure.
Both the right and left uterine arteries need to be blocked in this way. Usually it can all be done from the right groin. Some Radiologists prefer to perform the procedure using separate right and left groin punctures and a radical approach technique is gaining popularity, but gives no better results than from a groin approach.
The procedure finishes when there is no more blood flow into the fibroid. The catheter is withdrawn and the IR or nurse presses on the groin puncture site to prevent bleeding and then may put a small elastoplast over the wound.
On average, the procedure takes about 30 minutes.
You will be taken back to the recovery area or DCU on a trolley where you will be looked after by nurses who will take your pulse and blood pressure and check the wound.
You will need to lie still in bed for a few hours to reduce any chance of bleeding from the groin.
Most patients experience some degree of pelvic pain. This ranges from very mild to severe, crampy, period-like pain. This severe pain has been much better managed recently by the introduction of intra-arterial local anaesthtetic injections performed during the embolisation itself. Post procedural pain is further controlled with a cocktail of strong painkillers, which you will give yourself through the cannula (PCA - Patient Controlled Analgesia) that was inserted in your arm before the procedure as well as anti-cramping and anti-sickness drugs. The pain is worst in the first 8-12 hours. After intra arterial local anaesthetic many women experience little pain for the first 4-6 hours and when this anaesthetic wears off the degree of pain is significantly less and easier to manage.
The painkillers and sedatives may mean that you sleep for a few hours afterwards.
The drip and PCA will be discontinued the following morning to be replaced by the same cocktail of drugs in tablet form.
Most women stay in hospital for one night, although if you do need to stay in longer than a day, this is not a problem.
Most patients get a slight fever after the procedure. This is normal and is a good sign as it is due to the fibroid breaking down. The anti-inflammatory painkillers will help to control this fever.
The pain will probably still be present when you go home. You will be given painkillers to take home with you and you should rest for 3-4 days, drink plenty of fluids and stay as mobile as you can.
Women can go back to normal activities, including sport and sexual activity, as soon as they feel able.
Unlike most surgery, there is no muscle-cutting involved in UFE, so you are not at risk of bursting a wound or causing a hernia.
In order to avoid infection, it is advised that you do not use tampons or swim in non-chlorinated water if you have a discharge.
Most women are ready to go back to work after 3-14 days. It is probably best to allow for being off work for a fortnight.
How quickly will I start to feel the benefits? (see Figs. 5a & 5b)
Immediately after UFE, the fibroids become soft.
Pressure symptoms on the bladder and bowel and heavy periods usually respond within days.
Average fibroid volume reduction is 40% at 3 months, and 60% at one year.
Usually an ultrasound scan is performed after 1 month and an MRI scan after 3 months, and again a year after the procedure. If there is cause for concern or any worrying side effects earlier scanning can be performed.
It is usually the position, blood supply and location of fibroids that determine success.
The richer the blood supply to the fibroids, the better the response.
Submucus fibroids respond best, although intramural and sub-serosal ones also respond well.
Pedunculated fibroids (those with a stalk) can be successfully embolised as long as the width of the stalk is not too thin in relation to the size of the fibroid.
UFE can be combined with myomectomy using hysteroscopic, laparoscopic or abdominal routes to combine the success of these two complimentary treatment options.
They are the particles used to block the uterine arteries.
There are various different types, some of which dissolve and others which remain in the body.
They can never be 'dislodged'. Vigorous exercise, which increases the heart rate and therefore blood flow, will only jam the particles further into the blood vessel.
Tiny blood vessels in the uterus remain intact and keep the womb alive, while the fibroids, which are far more susceptible to a shortage of blood, die.
As yet, none of these embolic agents (listed below) has been proven to be more effective than the others.
1mm thick sponge is cut up into approximately 1mm cubes. This is dissolved in X-ray contrast agent to produce a slurry like wallpaper paste.
This is likely to block large and medium-sized uterine arteries, but leaves smallest arteries patent to allow maximum blood supply to the normal uterine tissue.
It dissolves in a few days or weeks, but completely 'dead' fibroids cannot regrow.
It has been in common use for over 20 years. It is more likely to leave the uterine arteries blocked than the other agents.
It may cause less post-procedural pain than PVA and other agents.
Different sized particles are used, usually 0.3-0.5mm or 0.5-0.7mm in size. In theory, these will block arteries down to these sizes, but in reality particles clump together to block the arteries, for example, if three 0.5mm particles clump together, they will block an artery of 1.5mm diameter. The level of arterial blockage may be similar to that seen with Spongistan slurry. The uterine arteries are more likely to re-open within 3 months.
This has also been in common use for over 25 years and is the most common agent used in the UK.
The first of the 'Spherical' embolic agents, these are 0.5-0.9mm non-dissolvable particles. They do not clump and therefore block arteries at a smaller diameter. The main uterine arteries usually remain open, but less than with Embozenes, Beadblock or PVA.
Blue coloured spherical PVA, commonly used in 0.7-1.2mm sizes. Less likely to permanently block uterine arteries, but may be less effective than the other agents in killing all the fibroids.
Colour coded Polyzene-F coated spherical embolic. Used in 0.7-1.3mm sizes. Leaves arteries open and is as effective as PVA, Embospheres and Gelatin sponge.
Optispheres (Gel-Bead) Bio-degradable Spheres
The newest embolic agent available and being trialled in 2017 and 2018. A Gelatin microsphere which potentially combines the advantages of a spherical agent getting deep fibroid penetration and so effectively 'killing' all fibroids with being a non-plastic, biodegradable agent allowing full uterine artery patency and preservation of both ovarian and uterine function to allow improved fertility outcomes. Results of trials performed by Dr Hacking due in 2018
What are the benefits of UFE compared to other treatments? (See Figs. 6a & 6b)
No scar.
Treats uterus up to and above the umbilicus.
Treats heavy periods with anaemia without surgery.
You retain your uterus.
There is no cutting and therefore no stitches nor scar.
No blood transfusion is required.
The likelihood of fibroids growing back is only around 20- 25% five years after treatment, much lower than after myomectomy.
Only 1-2 nights in hospital.
Approximately two weeks off work, often less.
No general anaesthetic required and you are conscious throughout the procedure.
If further treatment is necessary, myomectomy is a more successful operation if UFE has been performed first as the chance of uncontrollable bleeding, which can lead to hysterectomy, is much less likely.
There are risks attached to every medical procedure. The important thing is to weigh up the benefits of being treated against the risks of a rare complication happening to you. The risks of fibroid embolisation include:
Deaths have occurred with hysterectomy and myomectomy. Usually mortality figures of 1 in 1,500-3,000 for these two surgical techniques are quoted.
Death following UFE has been reported in 5 cases worldwide due to severe infection in 2 cases, pulmonary embolus in 2 others and unexpected shunting and multiple organ embolisation in a 5th case. This is from a total of between 150,000 and 200,000 cases performed worldwide, giving a mortality of 1 in 30,000 - 40,000.
It must be stressed that risk of death is very rare in any of these procedures.
True uterine infection is very rare, probably less than 1 in 1,000.
More commonly dead fibroid material can become lodged in the uterine cavity and if untreated can become infected. Signs of this include an unpleasant, foul smelling discharge, pain and fever.
This can often be predicted after embolising large submucosal or intracavity fibroids and can happen at any time up to 9 months after UFE. Detailed advice will be given to the patient, her Gynaecologist and GP about this possibility. The Interventional Radiologist should be contacted urgently to arrange antibiotics and scanning and if appropriate an urgent Gynaecological assessment.
True uterine infection will require antibiotics and probably urgent hysterectomy, but usually the uterus is intact and if the problem is one of fibroid passage then antibiotics and pain killers will usually suffice, and if not delivery of the fibroid by the gynaecologist or hysteroscopy with fibroid clearance will usually be possible.
Your Interventional Radiologist will ask you before UFE whether you would have a hysterectomy if your uterus became infected. If you would not, under any circumstances, then your radiologist is likely to advise you not to undergo embolisation.
This is due to accidental embolisation of the arteries to the two ovaries and is often the result of different arrangements of blood vessels in some patients. The greater the experience your Interventional Radiologist has and the use of larger embolic particles has made this complication very unlikely. The chances of premature menopause are less than 2% under the age of 45, rising each year up to around 15% at age 50. About 3 times as many patients have no periods for a month or two after UFE.
Embolisation with temporary or biodegradeable embolic agents such as Optisphere (Gel-Bead) and Gelfoam slurry are less likely to cause ovarian failure than with more permanent, especially smaller (<500micron size) 'plastic' embolics.
This happens in approximately 3-4% of all patients and usually occurs 6 weeks - 3 months afterUFE. It is most common with submucous fibroids, particularly if largely intra-uterine. Fibroids can either pass in large pieces or break up and pass unknowingly. The MRI scans in these cases can show a remarkably normal uterus on follow up imaging.
After passage of a fibroid and before you attempt prior to become pregnant, it is wise to have a hysteroscopy to observe if there are any significant intrauterine adhesions present, and treat if necessary.
This happens in about 4% of patients and is usually due to the fibroid breaking down. It normally lasts for around 2 weeks, though can go on intermittently for several months. If it is accompanied by fever, you should contact your Interventional Radiologist and Gynaecologist as soon as possible. You might need to have an internal exam to make sure the dead fibroid has not fallen down into the vagina or become stuck in the cervix, as this could cause infection.
Haematoma (bruise around entry point)
A small bruise in the groin or wrist if a radial approach was used is quite normal, but if it becomes bigger, it may need treating with antibiotics to prevent infection.
Fibroids fed by an additional blood supply (usually the ovarian arteries)
This happens in about 5 - 10% of cases. The ovarian arteries can be embolised. Using smaller 'plastic' embolic particales this is more likely to result in premature menopause if both ovarian arteries are blocked. The risks of Ovarian failure seem much lower using larger (>700micron) 'plastic' or either Gelfoam Slurry or the newer Optisphere (Gel-BEAD) dissolvable embolics. This option can be considered for women after discussion in womenwho have no further fertility wishes or whose fibroids are unlikely to be dealt with using uterine artery embolisation alone. Your Interventional Radiologist will talk to you about such wishes if it is found that the ovarian arteries are supplying the fibroids with blood.
The average age of women undergoing UFE is around 40, so natural fertility is already starting to decrease, even without the fibroids.
The Royal Colleges of Radiology (RCR) and Royal College of Obstetrics and Gynaecology (RCOG) currently advise women wanting to get pregnant, to obtain myomectomy for a large single or a small number of fibroids especially when they are subserosal or intramural. When they are small and submucosal or intracavity hysteroscopic myomectomy is preferable in experienced hands. UFE is probably now an acceptable alternative with large or particularly multiple fibroids and can be combined with myomectomy.
There is growing evidence that UFE may indeed be superior to open myomecomy in young women with multiple fibroids. Treatment success is high and fibroid recurrence rates are lower compared with myomectomy. Women can carry pregnancies after UFE, although unfortunately miscarriages do still occur. A woman carrying a pregnancy to full term may have a vaginal or natural childbirth after UFE whereas a caesearan section is usually advised in women who have undergone abdominal myomectomy. More and more studies have shown that ovarian function, as measured by the Anti-Muillerian Hormone levels is not adversely affected by the UFE procedure. The use of dissolvable Gel-Bead embolics agents raise the possibility that uterine function may be better maintained compared with other embolic agents although these claims are as yet unproven.
There have now been over 300 successful pregnancies after UFE.
An increasing number of centres are now offering UFE. This is a technique with quite a long learning curve and so experienced operators should be sought out wherever possible. For UFE at Southampton you will need a referral to an Interventional Radiologist from either your GP or your gynaecologist. If you wish to see an Interventional Radiologist out of your geographical area, you will need to ask the doctor who is referring you to obtain funding from his PCT.
All private insurance companies now cover for UFE. MRI scans will usually be charged on top of the usually quoted figures. UFE is available by Dr Nigel Hacking at a number of hospitals in Southampton, Trinidad and London.
A number of institutions will now quote for overseas patients. Travel arrangements and full costs should be included wherever possible. To arrange an appointment with Dr Nigel Hacking please click here.
An abnormal connection between two surfaces of the body. Full medical glossary
Various conditions caused by exaggerated reactions of the immune system (hypersensitivity reactions) to a variety of substances. Full medical glossary
A reduced level of haemoglobin, which carries oxygen in the blood. Anaemia causes tiredness, breathlessness and abnormally pale skin. Full medical glossary
A medication that reduces sensation. Full medical glossary
Any drug that suppresses inflammation Full medical glossary
Medication to treat infections caused by microbes (organisms that can't be seen with the naked eye), such as bacteria. Full medical glossary
A blood vessel that carries blood away from the heart. Apart from the pulmonary artery and umbilical artery, all arteries carry oxygenated blood. Full medical glossary
A fluid produced by the liver, which helps the fat ingested in food to combine with the digestive juices in the gut. Full medical glossary
The organ that stores urine. Full medical glossary
The pressure of blood within the arteries. Full medical glossary
A common name for the large and/or small intestines. Full medical glossary
A thin tube inserted into the body to administer medication, drain off fluid, or insert a surgical instrument. Full medical glossary
A tube used either to drain fluid from the body or to introduce fluid into the body. Full medical glossary
Any neck-like structure; most commonly refers to the neck of the uterus. Full medical glossary
A substance taken (either by mouth or into a vein) by a person who is about to undergo an imaging investigation, to improve the visibility of the structures being imaged. Also known as contrast medium. Full medical glossary
A substance taken (either by mouth or into a vein) by a person who is about to undergo an imaging investigation, to improve the visibility of the structures being imaged. Full medical glossary
A means for the continuous injection into a vein. Full medical glossary
A clot (or other material, for example, fat or air) that has become dislodged from a point in the blood system and travels in the circulation before lodging elswhere. Full medical glossary
The raising of the body temperature above norma, which may be accompanied by symptoms such as shivering, headache and sweating. Full medical glossary
A benign tumour, most often in the uterus. Full medical glossary
Benign tumours, most often in the uterus. Full medical glossary
Any agent that reduces or abolishes sensation, affecting the whole body. Full medical glossary
A collection of blood outside a blood vessel. It occurs when the wall of a blood vessel becomes damaged and blood leaks into surrounding tissue where it pools, such as in a bruise. Full medical glossary
The surgical removal of the uterus (womb). Full medical glossary
Examination of the inside of the uterus by endoscopy, using an instrument called a hysteroscope inserted through the vagina and cervix. Full medical glossary
Invasion by organisms that may be harmful, for example bacteria or parasites. Full medical glossary
Stopping or ceasing for a time. Full medical glossary
inside the uterus Full medical glossary
Within a vein. Full medical glossary
A keyhole surgical procedure. Full medical glossary
A large abdominal organ that has many important roles including the production of bile and clotting factors, detoxification, and the metabolism of proteins, carbohydrates and fats. Full medical glossary
A medication that reduces sensation in a part of the body. Full medical glossary
The time of a woman's life when her ovaries stop releasing an egg (ovum) on a monthly cycle, and her periods cease
The size of a micrometre, which is a one-thousandth of a millimetre Full medical glossary
The spontaneous loss of pregnancy. Full medical glossary
An abbreviation for magnetic resonance imaging, a technique for imaging the body that uses electromagnetic waves and a strong magnetic field. Full medical glossary
onychogryphosis Full medical glossary
relating to the ovaries Full medical glossary
Female reproductive organs situated one on either side of the uterus (womb). They produce egg cells (ova) and hormones in a monthly cycle. Full medical glossary
Relating to the pelvis. Full medical glossary
the period from conception to birth Full medical glossary
per vaginam Full medical glossary
A doctor specializing in the interpretation of imaging techniques for the diagnosis and assessment of disease. Full medical glossary
A microbe, such as a type of bacteria, that is able to resist the effects of antibiotics or other drugs. Full medical glossary
Relating to injury or concern. Full medical glossary
Medicine in a solid preparation administered via the rectum, the last part of the large intestine. Full medical glossary
A diagnostic method in which very high frequency sound waves are passed into the body and the reflective echoes analysed to build a picture of the internal organs – or of the foetus in the uterus. Full medical glossary
The process of using high-frequency sound waves to produce internal images of the body. Full medical glossary
The womb, where embryo implantation occurs and the growing foetus is nourished. Full medical glossary
The muscula passage, forming part of the femal reproductive system, between the cervix and the external genitalia. Full medical glossary
A blood vessel that carries blood towards the heart. Full medical glossary
Relating to the veins. Full medical glossary
The uterus. Full medical glossary
A type of electromagnetic radiation used to produce images of the body. Full medical glossary
Consultant Interventional Radiologist
Treatment options for uterine fibroids
Risks of a hysterectomy
Sunday, August 6, 2017 - 06:49
Who are the best doctors for office gynaecology?
Friday, July 14, 2017 - 14:49
How to deal with heavy periods
The 7 health treatments you need to know about
Sunday, April 2, 2017 - 19:32
Is your period pain bad enough to take a day off?
Wednesday, March 29, 2017 - 16:21
Can you have surgery without anaesthetic?
Tuesday, March 28, 2017 - 15:20
Twenty-five Harley Street celebrates
Non-invasive fibroid removal with the Myosure system: no hospital stay required
Uterine Fibroids Patient Engagement
Related articles by Dr Nigel Hacking
Introduction to Benign Prostatic Hyperplasia (BPH)
Prostate Artery Embolisation for BPH
Medical treatments for uterine fibroids
Mr Ertan Saridogan
Uterine Fibroids FAQs
Mr Adrian Lower
The causes of irregular and heavy periods
Modern Management of Uterine Fibroids
Pandelis Athanasias
Investigations used to establish a diagnosis of uterine fibroids
An Introduction to Fibroids


Super parcel of land for hunting, recreation or building site.
Land is level to rolling with stream, wildlife and seclusion.
Closing: Closing shall occur as soon as possible after applicable closing documents have been completed. Projected closing date is to be on or about August 1st, 2014.
Real Estate Taxes: Pro-rated to closing.


text:
from app import app, db, login_manager
from datetime import datetime
from passlib.apps import custom_app_context as pwd_context

roles_users = db.Table('roles_users',
                       db.Column('user_id', db.Integer(), db.ForeignKey('user.id')),
                       db.Column('role_id', db.Integer(), db.ForeignKey('role.id')))

class Role(db.Model):
    id = db.Column(db.Integer, primary_key=True)
    name = db.Column(db.String(80), unique=True)
    description = db.Column(db.String(255))

    def __repr__(self):
        return '<Role: %s>' % self.name

class User(db.Model):
    id = db.Column(db.Integer, primary_key=True)
    email = db.Column(db.String(255), unique=True)
    username = db.Column(db.String(100), unique=True)
    password_hash = db.Column(db.String(255))
    active = db.Column(db.Boolean())
    created_at = db.Column(db.DateTime())
    confirmed_at = db.Column(db.DateTime())
    roles = db.relationship('Role', secondary=roles_users, backref=db.backref('User', lazy='dynamic'))
    articles = db.relationship('Article', backref='User', lazy='dynamic')

    def __init__(self, email, username, password):
        # Normalize the email by stripping whitespace and lowercasing
        self.email = email.strip().lower()
        self.username = username
        # Hash the password
        self.hash_password(password)
        # Give the new user a default role, make sure to create this role first
        default_role = Role.query.filter_by(name=app.config['DEFAULT_ROLE']).first()
        self.roles.append(default_role)
        self.active = True
        self.created_at = datetime.utcnow()

    def hash_password(self, password):
        self.password_hash = pwd_context.encrypt(password)

    def verify_password(self, password):
        return pwd_context.verify(password, self.password_hash)

    def is_authenticated(self):
        return True

    def is_active(self):
        return self.active

    def is_anonymous(self):
        return False

    def get_id(self):
        return unicode(self.id)

    def __repr__(self):
        return '<User: %s>' % self.email

@login_manager.user_loader
def load_user(user_id):
    return User.query.get(int(user_id))

class Comment(db.Model):
    id = db.Column(db.Integer, primary_key=True)
    body = db.Column(db.Text)
    html = db.Column(db.Text)
    created_at = db.Column(db.DateTime())
    user_id = db.Column(db.Integer, db.ForeignKey("user.id"))
    visible = db.Column(db.Boolean())
    article_id = db.Column(db.Integer, db.ForeignKey('article.id'))

    def __repr__(self):
        return '<Comment: %s>' % self.body

class Tag(db.Model):
    __searchable__ = ['name', 'slug']

    id = db.Column(db.Integer, primary_key=True)
    name = db.Column(db.String(255), unique=True)
    slug = db.Column(db.Text)
    articles = db.relationship('Article', backref='Tag', lazy='dynamic')

    def __repr__(self):
        return '<Tag: %s>' % self.name

class Article(db.Model):
    id = db.Column(db.Integer, primary_key=True)
    title = db.Column(db.Text)
    body = db.Column(db.Text)
    html = db.Column(db.Text)
    slug = db.Column(db.Text)
    created_at = db.Column(db.DateTime())
    modified_at = db.Column(db.DateTime())
    publish_at = db.Column(db.DateTime())
    user_id = db.Column(db.Integer, db.ForeignKey('user.id'))
    visible = db.Column(db.Boolean())
    tag = db.Column(db.Integer, db.ForeignKey('tag.id'))

    def __repr__(self):
        return '<Article: %s>' % self.title

redpajama_set_name: RedPajamaGithub


Freezer Repair Advice from The Indesit Experts.
A noisy freezers isn't uncommon, especially on a new appliance.
Can I reverse the doors on my Indesit freestanding freezers?
There is an amber light on my Indesit freezers, what is it for?
Find every error code here for your Freezer.
Search for your Freezer manual using our search bar.